

Yourui Pharma completes Series B financing

29 June 2018 | News

Yourui Pharmaceuticals announced that it has been awarded a round of investment by Cambridge Capital to carry out the commercialization of high-value drugs in China



Yourui Pharmaceutical Technology is a leading specialty pharmaceutical company in China, headquarters in Shanghai. It has completed a Series B financing totaling US\$20 million and an additional US\$15 million in funding for the acquisition of new products.

Financing was led by Cambridge Capital, a private equity firm that specializes in R&D and commercialization opportunities in the growing Chinese healthcare market.

Neobridge Zhang, managing director of Cambridge Capital, will also join the board of directors of Utopec. B-Financing prepares Yourui Pharmaceuticals for the rapid expansion of innovative drug product portfolios.

With the broad global network of Cambridge Capital, it helps identify high-value licensing opportunities and develops innovative global pharmaceutical companies and biotech companies.

"This investment represents a unique financing model for building one of the top pharmaceutical companies in China," said Fu Wei, CEO of Cambridge Capital. "Yourui Pharmaceuticals leads the product from registration to listing. The ability of the process has been fully validated, coupled with its large sales organization and strong sales efficiency system, making it an ideal partner for the commercialization of innovative drug products in China."

The cooperation between Kangqiao and Youru has yielded some results: The agreement between Yourui and Pacira Pharmaceuticals of the United States has recently been announced.

The agreement aims to promote the use of Pacira's EXPAREL® (liposomal injection suspension for bupivacaine). The development and commercialization of China, which is a non-opioid agent, has been approved in the United States and can provide long-lasting analgesic and analgesic effects for postoperative patients. It was Cambridge Capital that saw the business opportunities with Pacira and promoted the agreement.